Wealth Enhancement Trust Services’s Ionis Pharmaceuticals IONS Stock Holding History

Wealth Enhancement Trust Services’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$159	Buy	+2	New	+$151	﹤0.01%	1381

Other funds holding IONS

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.32B AUM 32.9% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Wealth Enhancement Trust Services's IONS Position: Q2 2026 in Review

Wealth Enhancement Trust Services opened a new position in Ionis Pharmaceuticals (IONS) in Q2 2026: 2 shares worth $159. The stake represents ﹤0.01% of the portfolio and ranks #1381 among its holdings.

318 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Wealth Enhancement Trust Services held 2 shares of Ionis Pharmaceuticals worth $159 as of Q2 2026.
Ionis Pharmaceuticals was a new Wealth Enhancement Trust Services position in Q2 2026.
Ionis Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Trust Services's portfolio in Q2 2026, its #1381 holding.
318 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Trust Services's 13F filing for Q2 2026, filed 15 Jul 2026.